| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 18/11/2024 | 18:23 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:SNY | Sanofi |
| 15/11/2024 | 06:59 | GlobeNewswire Inc. | Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU) | NASDAQ:SNY | Sanofi |
| 06/11/2024 | 07:00 | GlobeNewswire Inc. | Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis | NASDAQ:SNY | Sanofi |
| 28/10/2024 | 22:56 | PR Newswire (Canada) | L'immunisation par Beyfortus® pour protéger les nourrissons contre le VRS a commencé | NASDAQ:SNY | Sanofi |
| 28/10/2024 | 22:54 | PR Newswire (Canada) | Beyfortus® immunization to protect infants from RSV has begun | NASDAQ:SNY | Sanofi |
| 25/10/2024 | 12:05 | IH Market News | Capri Shares Crash 45% After Merger Block; Coursera Falls 18% on Lower Revenue Forecast | NASDAQ:SNY | Sanofi |
| 21/10/2024 | 11:47 | IH Market News | Spirit’s Stock Surges 56% on Refinancing; Starboard Invests in Kenvue; Cigna-Humana Merger Back in Negotiations | NASDAQ:SNY | Sanofi |
| 17/10/2024 | 08:35 | Business Wire | Sanofi and Orano Join Forces to Develop Next-generation Radioligand Medicines | NASDAQ:SNY | Sanofi |
| 17/10/2024 | 08:35 | Business Wire | Sanofi et Orano Med unissent leurs forces pour développer des radiothérapies internes vectorisées de nouvelle génération | NASDAQ:SNY | Sanofi |
| 16/10/2024 | 18:26 | PR Newswire (US) | FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals | NASDAQ:SNY | Sanofi |
| 16/10/2024 | 12:00 | PR Newswire (US) | Sanofi commits $18 million to Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine to increase diversity in clinical studies | NASDAQ:SNY | Sanofi |
| 11/10/2024 | 12:31 | IH Market News | BP Signals Rising Net Debt; Tesla Slumps; Stellantis CEO Announces Retirement; Berkshire Trims BofA Stake, and More | NASDAQ:SNY | Sanofi |
| 27/09/2024 | 15:35 | GlobeNewswire Inc. | Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD | NASDAQ:SNY | Sanofi |
| 27/09/2024 | 13:00 | GlobeNewswire Inc. | Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD) | NASDAQ:SNY | Sanofi |
| 23/09/2024 | 12:32 | IH Market News | Apollo Eyes $5 Billion Investment in Intel; TSMC and Samsung Explore UAE Chip Projects, and More | NASDAQ:SNY | Sanofi |
| 20/09/2024 | 13:45 | GlobeNewswire Inc. | Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old | NASDAQ:SNY | Sanofi |
| 16/09/2024 | 14:00 | PR Newswire (US) | Sanofi shipping BEYFORTUS® in US to help protect babies against RSV disease; new manufacturing line approved by FDA | NASDAQ:SNY | Sanofi |
| 13/09/2024 | 18:15 | GlobeNewswire Inc. | Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) | NASDAQ:SNY | Sanofi |
| 12/09/2024 | 08:37 | Business Wire | Accord de licence entre Sanofi, RadioMedix et Orano Med pour le développement d’une nouvelle génération de radiothérapies internes vectorisées contre les cancers rares | NASDAQ:SNY | Sanofi |
| 12/09/2024 | 08:37 | Business Wire | Sanofi, RadioMedix, and Orano Med Announce Licensing Agreement on Next-Generation Radioligand Medicine for Rare Cancers | NASDAQ:SNY | Sanofi |
| 13/08/2024 | 15:06 | Edgar (US Regulatory) | Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] | NASDAQ:SNY | Sanofi |
| 13/08/2024 | 12:30 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:SNY | Sanofi |
| 26/07/2024 | 18:08 | PR Newswire (Canada) | Le vaccin FluzoneMD Haute Dose Quadrivalent demeure le vaccin préférentiellement recommandé pour protéger les adultes de 65 ans et plus contre la grippe | NASDAQ:SNY | Sanofi |
| 26/07/2024 | 17:17 | PR Newswire (Canada) | Fluzone® High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza | NASDAQ:SNY | Sanofi |
| 25/07/2024 | 12:19 | IH Market News | Earnings Updates: Ford Shares Fall 13% on EPS Miss, Stellantis Down 6%, Viking Therapeutics Up 20%, Unilever Up 5% | NASDAQ:SNY | Sanofi |
| 10/07/2024 | 22:10 | PR Newswire (US) | Sanofi ships U.S. influenza vaccines for the 2024/25 season | NASDAQ:SNY | Sanofi |
| 09/07/2024 | 12:54 | IH Market News | BP Slashes Profit Forecast by $700 Million; Morgan Stanley Predicts S&P 500 10% Drop, and More News | NASDAQ:SNY | Sanofi |
| 26/06/2024 | 23:30 | GlobeNewswire Inc. | Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine | NASDAQ:SNY | Sanofi |
| 06/06/2024 | 13:00 | PR Newswire (US) | I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer | NASDAQ:SNY | Sanofi |
| 31/05/2024 | 22:30 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:SNY | Sanofi |